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Background: Chromosomal microarray (CMA) is currently the first-tier genetic test for patients with idiopathic
neuropsychiatric diseases in many countries. Its improved diagnostic yield over karyotyping and other molecular
testing facilitates the identification of the underlying causes of neuropsychiatric diseases. In this study, we applied
oligonucleotide array comparative genomic hybridization as the molecular genetic test in a Chinese cohort of
children with DD/ID, autism or MCA.
Results: CMA identified 7 clinically significant microduplications and 17 microdeletions in 19.0% (20/105) patients,
with size of aberrant regions ranging from 11 kb to 10.7 Mb. Fourteen of the pathogenic copy number variant
(CNV) detected corresponded to well known microdeletion or microduplication syndromes. Four overlapped with
critical regions of recently identified genomic syndromes. We also identified a rare de novo 2.3 Mb deletion at
8p21.3-21.2 as a pathogenic submicroscopic CNV. We also identified two novel CNVs, one at Xq28 and the other at
12q21.31-q21.33, in two patients (1.9%) with unclear clinical significance. Overall, the detection rate of CMA is
comparable to figures previously reported for accurately detect submicroscopic chromosomal imbalances and
pathogenic CNVs except mosaicism, balanced translocation and inversion.
Conclusions: This study provided further evidence of an increased diagnostic yield of CMA and supported its use
as a first line diagnostic tool for Chinese individuals with DD/ID, ASD, and MCA.
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Multiple congenital anomaliesBackground
Array comparative genomic hybridization (aCGH) and
single nucleotide polymorphism (SNP) genotyping array,
collectively referred to as chromosomal microarray ana-
lysis (CMA), is commonly applied as a clinical diagnostic
tool for patients with intellectual disabilities/developmental
delay (ID/DD), autism spectrum disorders (ASD), and mul-
tiple congenital anomalies (MCA). With rapid advances in* Correspondence: richardchoy@cuhk.edu.hk
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unless otherwise stated.microarray resolution and throughput over the past few
years, CMA has consistently shown a higher diagnostic
yield than conventional karyotyping [1-5]. The Inter-
national Collaboration for Clinical Genomics (ICCG), also
known as International Standard for Cytogenomic Array
(ISCA) Consortium, has recommended CMA over the
karyotyping as the first-tier cytogenetic diagnostic test for
patients with ID/DD and MCA [6]. Standards and guide-
lines recommended by American College of Medical
Genetics (ACMG) have also been publised to standardise
and improve the quality of CMA among different clinical
genetic laboratories [7,8].Ltd. This is an Open Access article distributed under the terms of the Creative
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cated in the pathogenesis of many neuropsychiatric
diseases despite the appreciation of the abundance of
common CNVs in normal individuals [9,10]. Several
studies have elucidated the causative role of CNV in
DD/ID, ASD [11], congenital heart diseases [12], epi-
lepsy [13], and congenital kidney malformation [14].
However, these studies also illustrated the phenotypic
heterogeneity associated with a particular CNV. That is,
the same CNV may confer risk to multiple diseases;
other additional risk factors are required for the devel-
opment of a specific disease outcome. This has led to
the “two-hit” theory [15,16]. Under this circumstance,
the clinical diagnosis, genetic counseling and manage-
ment become challenging. An evidence-based approach
which is dependent on the accumulation and delivery of
knowledge through internet resources has been estab-
lished to facilitate the result interpretations [17,18].
In this study, a high resolution 180 K oligonucleotide-
CMA was applied in a Chinese cohort of patients with
DD/ID, ASD, and MCA. The CMA findings were inter-
preted using the evidence-based workflow as recommended
by ICCG and ACMG for molecular diagnosis of constitu-
tional chromosomal and subchromosomal imbalances.
Results
CMA validation
To validate the CMA platform in this study, we first
tested 10 cases of numerical chromosomal abnormalities
including 7 trisomy cases (13, 16, 18, 21 and 22) and 3
monosomy cases (18, 21 and X). Subsequently 10 nor-
mal cases by karyotyping of normal individual were also
included in the validation set. The CMA results were in
100% concordnace with karyotyping. The final set in-
cluded 10 cases with known microscopic or submicro-
scopic chromosomal abnormalities (7 by karyotyping,
2 by multiplex ligation-dependent probe amplification,
and one by multiplex ligation-dependent probe amplifi-
cation and fluorescence in situ hybridization). Patho-
genic CNV (pCNV) were detected in 7 cases (Additional
file 1) and were concordant with the previous findings.
The remaining cases without pCNV detected by CMA
were mosaic marker chromosome, balanced structural
rearrangement of chromosome 4, and balanced inversion
of chromosome 12.
Detection rate of pathogenic CNV in a postnatal cohort
A total of 105 patients with MR/DD/ASD/MCA referred
to clinical genetics service were recruited for CMA ap-
plication study. Custom-designed arrays precluding most
of benign CNV as catalogued by Database of Genomic
Variants (DGV) were applied in 67 patients (63.8%)
while ISCA array were used in another 38 patients
(36.2%). The average numbers of CNV found per patientusing custom-designed array and ISCA array were 3
CNVs and 16 CNVs, respectively.
The detection rates of pathogenic CNV from custom-
designed and ISCA array were 17.9% and 21.1%, respect-
ively, with an overall detection rate of 19.0%. A total of
24 CNVs (7 microduplications and 17 microdelections)
in 20 patients were considered pathogenic (Figure 1).
The size of the pathogenic CNV (pCNV) ranged from
11 kb to 7.1 Mb (Additional file 2). Recurrent pCNV
were most frequently observed at the 22q11.2 region
in this cohort, with two 22q11.2 duplications (MIM
608363) and three 22q11.2 deletions (Velocardiofacial/
DiGeorge syndrome; MIM 188400) being identified.
Deletions in the chromosomal region of 2q37.1-q37.3
known to cause the brachydacytly-mental retardation
syndrome were the second most common pCNV. Three
patients carried the submicroscopic deletions with an
overlapping region of 2.7 Mb encompassing the critical
HDAC4 gene which is responsible for the phenotype.
Three cases of pCNV each corresponding to Prader-
Willi syndrome (MIM 176270), WAGR syndrome (MIM
612469), and 3q29 microdeletion (MIM 609425) were
also identified.
Seven cases bearing rare CNV which overlapping with
the critical regions of emerging genetic syndromes were
identified and were considered pathogenic. These includ-
ing five microdeletions (1q21.3-q22, 4q35.2, 10q23.1,
14q22.1-q22.3 and 21q22.13) and two microduplications
(17q25.1-q25.3 and 13q21.2) as reported previously
(Additional file 2). One patient was diagnosed with mod-
erate DD, autistic features, hypotonia, and dermoid cyst
over scalp. CMA showed a de novo 2.3 Mb deletion at
8p21.3-21.2 encompassing 37 genes. Although there was
no known microdeletion syndrome associated with this
region, we considered it pathogenic based on its size, de
novo nature, and its overlapping with 70% of the patho-
genic variant found in one DD +DM case (nssv578268)
from the ISCA database and a similar 8p21 microdeletion
being reported in a patient with ID and behavioral
abnormalities.
There were two cases with duplication and deletion of
size 1.33 and 6.22 Mb, respectively that were considered
to bear a variant of unclear clinical significance (VOUS).
The first case (aCGH3704) carried a 6.22 Mb deletion at
12q21.31-q21.33. The microdeletion was inherited from
a physiologically healthy father and the patient does
not carry any symptoms related to Bardet-Biedl syn-
drome. Bardet-Biedl syndrome is typically inherited in
an autosomal recessive manner. For the second case
(aCGH1293), it carries a 1.33 Mb microduplication con-
taining the MECP2 region. The X-chromosome inactiva-
tion (XCI) pattern has not been analyzed in the female
patient and the GDI1 gene was not involved, therefore
we regarded these two microduplications as VOUS.
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Figure 1 An overview of pathogenic CNV found in this study. Copy number loss is shown as red (left) and copy number gain in blue (right),
respectively. The length of the bar indicating the size of each aberrant region.
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This is the first study describing the use of CMA in a
Chinese cohort of patients with DD/ID, MCA, and
autism referred for clinical genetics testing. The CMA
platform was first validated in patients with known ab-
normal cytogenetic and molecular findings. Microscopic
or submicroscopic chromosomal imbalances were accur-
ately detected by CMA with improved resolution, the
breakpoints of aberrant regions could be more precisely
defined (Additional file 1). The advantage of increased
precision in delineation of breakpoints facilitates the
identification of the disease-causing genes [6]. The
superiority of CMA over karyotyping has also been
demonstrated in several cases. For instance, in a case of
marker chromosome of unknown origin detected by
karyotyping, CMA detected a 7.4 Mb duplication at
15q11.2-q13.1. This provided a clue to the origin of the
marker chromosome and explained the phenotype of
15q11-q13 duplication syndrome as observed in this
patient. In another patient with normal karyotype,
CMA revealed a complex chromosome rearrangement
involving a 10.7 Mb duplication at 2q36.1-q37.1 and a
9.7 Mb deletion at 2q37.1-q37.3. The size of individual
aberration was clearly within the detection range bykaryotyping (>5 Mb). However, the close proximity of
these two aberrant regions resulting in small net gain of
genomic materials (<1 Mb) which precluded its detec-
tion by karyotyping. In general, the limitations of CMA
including its inability to detect low level mosaicism,
heterochromatic abberrations, inversion and balanced
translocation, were inherent to this platform [6,19].
In this study, twenty patients (19.0%) with DD/ID,
ASD, and MCA were found to have at least one patho-
genic CNV. The detection rate achieved in this study
was similar to previous studies irrespective of the choice
of oligonucleotide-based (13-28%) [20-26] or SNP-based
platforms (15-19%) [27-29]. Improvement in the diagnos-
tic yield of CMA is initially contributed by the increased
genomic coverage and resolution of oligonucleotide arrays
over bacterial artificial chromosome (BAC) arrays among
aCGH platforms [30]. Both lower probe density and differ-
ence in genomic coverage may contribute to the lower
detection rate. This is exemplified by the lower probe
density custom designed 44 K array used in the majority
of the cases which might contributed to a lower positive
rate (17.9%) as expected compared to the higher density
probe ISCA 180 K design (21.1%,). However, the smaller
size of CNV identified were mostly benign. This is in
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pathogenic CNV are >400 kb in size [6]. Our data sug-
gested that appropriate size filter could be introduced to
decrease the false positive calls.
Fourteen pCNV corresponded to the well known micro-
deletion or microduplication syndromes were identified.
Velocardiofacial/DiGeorge syndrome, 22q11.2 duplication,
brachydacytly-mental retardation syndrome, and Prader-
Willi syndrome were among the most common recurrent
genomic disorders observed in many different populations.
They are known to be mediated by nonallelic homologous
recombination (NAHR) between regions of segmental
duplication. Our results also indicated that the pathogenic
CNV associated with DD/ID, autism, and MCA were also
largely contributed by NAHR in our study cohort.
We identified a rare microduplictaion (a de novo
2.3 Mb duplication) at 16p13.3 in a patient with
dysmorphism, mild MR, camptodactyly, tracheomalacia
in early childhood, blepharophimosis, and ptosis in
adulthood. This region encompasses the CREBBP gene.
Deletion of this gene is known to cause Rubinstein-Taybi
syndrome [31] while its duplication is responsible for
the observed phenotypes in chromosome 16p13.3 dupli-
cation syndrome which occurs in a frequency of 1 in
97,000 to 146, 000 live births [32].
Two CNV were classified as VOUS in two female
patients. A de novo Xq28 duplication was identified
in a patient with mild DD, DM, MCA, and hypotonia
(Additional file 2). Xq28 duplication syndrome (MIM
300815) was first suspected given the cytoband location
and the observed phenotype of DD. However, detailed
genomic location as depicted by CMA showed that the
critical 0.3 Mb region of Xq28 including the GDI1 gene
was not involved in our case. Instead, the duplicated re-
gion encompassed another set of genes which are known
to cause several genomic syndromes only when they are
deleted or mutated. In addition, there were no report of
case with similar duplications from ISCA or DECIPHER
database. In the second case, a paternally inherited dele-
tion of 12q21.31-q21.33 was found in a patient with ID
and DM. Although the father was phenotypically normal,
the pathogenicity of this region could not be excluded.
Homozygous deletion of CEP290 (OMIM*610142) and
ALX1 (OMIM*601527) in this region are associated with
different neurological diseases, but our case is a gain of
copy number. Therefore, we considered these two micro-
duplication regions as VOUS.
Conclusions
In summary, our study has demonstrated the success of
CMA application in patients with DD/ID, ASD, and
MCA of a Chinese cohort. The interpretation of CMA
findings was facilitated by publicly available databases,
such as ISCA, DECIPHER, and DGV.Methods
Patients
One hundred and fifteen patients with ID, DD, autism,
or MCA from Clinical Genetic Service of the Depart-
ment of Health of Hong Kong were recruited, both
prospectively and retrospectively, in this study (IRB ap-
proval: LM/283/2010). All patients and their parents
were studied by conventional karyotyping to exclude any
inherited microscopic chromosomal abnormalities or
balanced carrier status. Ten of them who had known
genomic imbalances based on prior cytogenetic and/or
molecular findings were chosen for platform validation. In
addition, 10 prenatal samples with known numerical
chromosomal abnormalities and 10 samples from adults
with normal karyotype were recruited for the validation
study. Another 105 patients without prior knowledge of
genomic aberrations were recruited for application study
and investigated by validated CMA. Informed consent was
obtained from parents or guardians. Ethical approval of
the study protocol was obtained from Ethics Committee
of the Department of Health, Hong Kong. DNA was
extracted from peripheral blood using DNeasy blood &
tissue kit (Qiagen) according to manufacturer’s instructions.
Genomic DNA concentration was measured by Nanodrop
spectophotometer (ThermoFisher).
CMA
The aCGH platform from Agilent Technologies was
employed in this study. Custom-designed 44 K as described
previously [33] and ISCA designed 180 K oligonucleotide
microarrays were used. Both designs had similar genomic
coverage for interrogation of over 100 genetic disorders but
were different in probe density giving average genome-wide
resolution of 100 kb and 25 kb, respectively.
Experimental procedures were performed according
to manufacturer’s description. Briefly, one microgram of
patient’s DNA and normal female control DNA (Promega)
were differentially labeled with Cy5 and Cy3 respectively
using Agilent SureTag Complete DNA Labeling Kit (Agi-
lent Technologies, USA). Labeled DNA was then cleaned
by purification columns (Agilent Technologies, USA) and
hybridized on microarray for 24 hours. Microarray wash-
ing and scanning was performed using Agilent Oligo
aCGH Wash Buffers (Agilent Technologies, USA) and
Agilent Microarray Scanner (Agilent Technologies, USA)
according to manufacturer’s instructions. All pathogenic
CNVs were further validated on NimbleGen CGX-135 K
array which were designed by Signature Genomics (Perkin
Elmer, USA) following manufacturer’s instructions.
Data analysis
Microarray images were processed with Feature Extrac-
tion v.11.1 (Agilent Technologies, USA) and imported to
Agilent Genomic Workbench 7.0.4.0 for analysis. CNV
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calls. Specifically, any aberration call with less than five
probes and the value of log2 ratio in gain <0.25 or loss
<0.5 was filtered. Parental aCGH were also performed to
determine the origin of CNV if needed. CNV were con-
sidered pathogenic if they overlapped with the critical
regions of well-characterized duplication/deletion syn-
dromes or pathogenic regions as reported in ISCA or
DatabasE of Chromosomal Imbalance and Phenotype in
Humans using Ensembl Resources (DECIPHER) data-
base, or were relatively large and encompassing many
genes. Benign CNVs are those frequently seen among
healthy individuals in the normal population as catalo-
gued in the DGV. CNVs that contained a small number
of genes but did not overlap with regions of known du-
plication/deletion syndrome, and that were not normal
CNVs reported in the DGV, were regarded as VOUS
(variant of uncertain clinical significance).
Additional files
Additional file 1: Validation of CMA platform using samples with
abnormal results in previous test.
Additional file 2: CMA with pCNV or VOUS findings for chinese
cohort of patients with intellectual disabilities/developmental delay,
autism and MCA. Notes: NA = not applicable [34-40].
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